Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900203 | PMC |
| http://dx.doi.org/10.1148/radiol.2019192090 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Quantifying morphologic variations as an alternate to standard response criteria for unresectable primary liver tumors after checkpoint inhibition therapy.
Radiol Med
December 2024
Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Purpose: The aim of this study was to assess the feasibility of quantifying morphologic changes in tumors during immunotherapy, as a reflection of response or survival.
Methods And Materials: A retrospective single-center analysis was performed in patients with unresectable liver cancer previously enrolled in clinical trials combining immunotherapy (tremelimumab ± durvalumab) and locoregional treatment (either ablation or transarterial chemoembolization). Conventional response (RECIST 1.
Efficacy and features of balloon-occluded transarterial chemoembolization for hepatocellular carcinoma: a narrative review.
Transl Gastroenterol Hepatol
June 2024
Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Background And Objective: Systemic therapy for hepatocellular carcinoma (HCC) is recommended in transarterial chemoembolization (TACE)-refractory and unsuitable cases. In Japan, TACE is broadly classified into conventional TACE (C-TACE), balloon occluded TACE (B-TACE), and drug-eluting beads TACE. However, the type of TACE recommended for TACE-refractory or unsuitable cases has not been elucidated, and a targeted approach for individual cases and appropriate TACE selection is important.
View Article and Find Full Text PDFNew insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.
Chin J Cancer Res
April 2024
Department of Nuclear Medicine, the Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou 213001, China.
Hepatocellular carcinoma (HCC) is responsible for a significant number of cancer-related deaths worldwide and its incidence is increasing. Locoregional treatments, which are precision procedures guided by imaging to specifically target liver tumors, play a critical role in the management of a substantial portion of HCC cases. These therapies have become an essential element of the HCC treatment landscape, with transarterial chemoembolization (TACE) being the treatment of choice for patients with intermediate to advanced stages of the disease.
View Article and Find Full Text PDFRole of Flex-Dose Delivery Program in Patients Affected by HCC: Advantages in Management of Tare in Our Experience.
J Clin Med
April 2024
Unit of Interventional Radiology, Department of Radiology, Ospedale Maggiore della Carità, Corso Giuseppe Mazzini 18, 28100 Novara, Italy.
: Introduced in the latest BCLC 2022, endovascular trans-arterial radioembolization (TARE) has an important role in the treatment of unresectable hepatocellular carcinoma (HCC) as a "bridge" or "downstaging" of disease. The evolution of TARE technology allows a more flexible and personalized target treatment, based on the anatomy and vascular characteristics of each HCC. The flex-dose delivery program is part of this perspective, which allows us to adjust the dose and its radio-embolizing power in relation to the size and type of cancer and to split the therapeutic dose of Y90 in different injections (split-bolus).
View Article and Find Full Text PDFHepatic Hemangioma: Review of Imaging and Therapeutic Strategies.
Medicina (Kaunas)
March 2024
Department of General, Interventional and Neuroradiology, Wroclaw Medical University, 50-367 Wrocław, Poland.
Hepatic hemangiomas are the most common benign liver tumors. Typically, small- to medium-sized hemangiomas are asymptomatic and discovered incidentally through the widespread use of imaging techniques. Giant hemangiomas (>5 cm) have a higher risk of complications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!